References
- Solheim TS, Fearon KC, Blum D, Kaasa S. Non-steroidal anti-inflammatory treatment in cancer cachexia: A systematic literature review. Acta Oncol 2013;52:6–17.
- Jones LW, Alfano CM. Exercise-oncology research: Past, present, and future. Acta Oncol 2013;52:195–215.
- Henderson RH, Hoppe BS, Marcus RB, Jr., Mendenhall WM, Nichols RC, Li Z, et al. Urinary functional outcomes and toxicity five years after proton therapy for low- and intermediate-risk prostate cancer: Results of two prospective trials. Acta Oncol 2013;52:463–9.
- Nielsen MH, Berg M, Pedersen AN, Andersen K, Glavicic V, Jakobsen EH, et al. Delineation of target volumes and organs at risk in adjuvant radiotherapy of early breast cancer: National guidelines and contouring atlas by the Danish Breast Cancer Cooperative Group. Acta Oncol 2013;52:703–10.
- Wennberg B, Lax I. The impact of fractionation in SBRT: Analysis with the linear quadratic model and the universal survival curve model. Acta Oncol 2013;52:902–9.
- Randen M, Helde-Frankling M, Runesdotter S, Strang P. Treatment decisions and discontinuation of palliative chemotherapy near the end-of-life, in relation to socioeconomic variables. Acta Oncol 2013;52:1062–6.
- Krishna MC, Matsumoto S, Saito K, Matsuo M, Mitchell JB, Ardenkjaer-Larsen JH. Magnetic resonance imaging of tumor oxygenation and metabolic profile. Acta Oncol 2013;52:1248–56.
- Lissbrant IF, Garmo H, Widmark A, Stattin P. Population-based study on use of chemotherapy in men with castration resistant prostate cancer. Acta Oncol 2013;52:1593–601.
- Grau C, Hoyer M, Alber M, Overgaard J, Lindegaard JC, Muren LP. Biology-guided adaptive radiotherapy (BiGART) – more than a vision?Acta Oncol 2013;52:1243–7.
- Glimelius B. 50 years with Acta Oncologica. Acta Oncol 2013;52:1–2.
- Dalton SO, Johansen C. New paradigms in planning cancer rehabilitation and survivorship. Acta Oncol 2013;52:191–4.